TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

PANCREAZE

PANCRELIPASE (AMYLASE
Approved 2010-04-12

PANCREAZE is a pancreatic enzyme product indicated for the treatment of exocrine pancreatic insufficiency. The medication is approved for use in both adult and pediatric patient populations. It serves as a therapeutic replacement for digestive enzymes that are normally secreted by the pancreas to facilitate the breakdown of nutrients.

Source: FDA Label • VIVUS INC

How PANCREAZE Works

PANCREAZE contains a mixture of lipases, proteases, and amylases that catalyze the hydrolysis of fats, proteins, and starches in the duodenum and proximal small intestine. These enzymes break down fats into monoglycerides and glycerol, proteins into peptides and amino acids, and starches into dextrins and short-chain sugars. By performing these actions, the medication mimics the physiological activity of digestive enzymes naturally secreted by the pancreas.

Source: FDA Label
1
Indication
--
Phase 3 Trials
15
Years on Market

Details

Status
Prescription
First Approved
2010-04-12
Routes
ORAL
Dosage Forms
CAPSULE, DELAYED RELEASE

Companies

Active Ingredient: PANCRELIPASE (AMYLASE , LIPASE , PROTEASE)

PANCREAZE Approval History

Loading approval history...

What PANCREAZE Treats

1 indications

PANCREAZE is approved for 1 conditions since its original approval in 2010. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Exocrine Pancreatic Insufficiency
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PANCREAZE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

PANCREAZE is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. PANCREAZE ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.